BIOS - バイオスクリプ （BioScrip Inc.） バイオスクリプBIOSのチャート
BIOSの企業情報
| symbol | BIOS |
|---|---|
| 会社名 | BioScrip Inc （バイオスクリプ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Nursing Services |
| 業種 | ヘルスケア施設_サ―ビス 医療関連（Health Care） |
| 概要 | 事業概要 バイオスクリップ（BioScrip Inc.）は注入液ソリューションを提供する会社である。同社は、医師、病院システム、専門看護施設、医療従事者、製薬会社と提携して、患者に急性期後ケアサービスを提供する。同社は注入液サービスセグメントで30以上州の約70のサービス場所を通じて事業を運営する。同社が提供する自宅注入液サービスは臨床管理サービスと処方薬の配達を提供する。同社患者の医師の指導と調整によるサービスを提供する。同社の薬剤師、看護師、栄養士、呼吸療法認定士を含む多分野臨床医チームは医師と協力して患者の特定のニーズに適したケア計画を立てる。同社のプラットフォームは患者へコミュニティベースおよび家庭ベースのケア環境を提供する。 バイオスクリプは米国で在宅点滴と在宅医療サ―ビスを提供。患者宅で抗菌薬、栄養、抗がん剤、免疫グロブリンの点滴剤の準備、投与、治療指導のほか、呼吸療法、医療器具を提供。また、処方薬の割引購入プログラム、薬剤給付プラン設計、薬剤使用状況の評価などの薬剤給付管理サ―ビスを行う。 Option Care Health, Inc. provides home and alternate site infusion services. The company was founded in 1996 and is headquartered in Bannockburn, IL. |
| 本社所在地 | 1600 Broadway Suite 700 Denver CO 80202 USA |
| 代表者氏名 | Daniel E. Greenleaf ダニエル・E・グリーンリーフ |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 720-697-5200 |
| 設立年月日 | 35125 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 2154人 |
| url | www.bioscrip.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bios |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 40.57200 |
| 終値（lastsale） | 3.04 |
| 時価総額（marketcap） | 389260210.88 |
| 時価総額 | 時価総額（百万ドル） 394.38200 |
| 売上高 | 売上高（百万ドル） 725.64700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 954.31900 |
| 当期純利益 | 当期純利益（百万ドル） -122.05800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 BioScrip Inc revenues decreased 21% to $344.4M. Net loss applicable to common stockholders excluding extraordinary items decreased 37% to $33.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Loss on extinguishment of debt decrease from $13.5M (expense) to $0K Bad Debts decrease from $13.2M (expense) to $0K. |
BIOSのテクニカル分析
BIOSのニュース
BioScrip, Inc.'s Shares March Higher, Can It Continue? 2019/06/18 10:14:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in BioScrip.
BioScrip (BIOS) Up 5.2% Since Last Earnings Report: Can It Continue? 2019/06/01 13:31:55 Zacks Investment Research
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioScrip's Option Care Merger on Track, Q1 Loss Narrows 2019/05/09 09:36:00 Zacks Investment Research
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.
BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release 2019/05/02 14:33:06 Zacks Investment Research
BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioScrip (BIOS) Reports Q1 Loss, Tops Revenue Estimates 2019/05/02 12:35:10 Zacks Investment Research
BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
BioScrip, Inc.'s Shares March Higher, Can It Continue? 2019/06/18 10:14:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in BioScrip.
BioScrip (BIOS) Up 5.2% Since Last Earnings Report: Can It Continue? 2019/06/01 13:31:55 Zacks Investment Research
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioScrip's Option Care Merger on Track, Q1 Loss Narrows 2019/05/09 09:36:00 Zacks Investment Research
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.
BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release 2019/05/02 14:33:06 Zacks Investment Research
BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioScrip (BIOS) Reports Q1 Loss, Tops Revenue Estimates 2019/05/02 12:35:10 Zacks Investment Research
BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
BioScrip, Inc.'s Shares March Higher, Can It Continue? 2019/06/18 10:14:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in BioScrip.
BioScrip (BIOS) Up 5.2% Since Last Earnings Report: Can It Continue? 2019/06/01 13:31:55 Zacks Investment Research
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioScrip's Option Care Merger on Track, Q1 Loss Narrows 2019/05/09 09:36:00 Zacks Investment Research
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.